The impact of dietary isoflavonoids on malignant brain tumors

Tina Sehm1, Zheng Fan1, Ruth Weiss1, Marc Schwarz2, Tobias Engelhorn2, Nirjhar Hore1, Arnd Doerfler2, Michael Buchfelder1, Ilker Y. Eyüpoglu1,a & Nic E. Savaskan1,a

1Department of Neurosurgery, Erlangen University Medical School, Friedrich Alexander University Erlangen-Nuremberg (FAU), Schwabachanlage 6 (Kopfklinik), D-91054 Erlangen, Germany
2Department of Neuroradiology, Erlangen University Medical School, Friedrich Alexander University Erlangen-Nuremberg (FAU), Schwabachanlage 6 (Kopfklinik), D-91054 Erlangen, Germany

Keywords
Angiogenesis, experimental therapeutics, microenvironment, nutrition

Abstract
Poor prognosis and limited therapeutic options render malignant brain tumors one of the most devastating diseases in clinical medicine. Current treatment strategies attempt to expand the therapeutic repertoire through the use of multimodal treatment regimens. It is here that dietary fibers have been recently recognized as a supportive natural therapy in augmenting the body’s response to tumor growth. Here, we investigated the impact of isoflavonoids on primary brain tumor cells. First, we treated glioma cell lines and primary astrocytes with various isoflavonoids and phytoestrogens. Cell viability in a dose-dependent manner was measured for biochanin A (BCA), genistein (GST), and secoisolariciresinol diglucoside (SDG). Dose response action for the different isoflavonoids showed that BCA is highly effective on glioma cells and nontoxic for normal differentiated brain tissues. We further investigated BCA in ex vivo and in vivo experimentations. Organotypic brain slice cultures were performed and treated with BCA. For in vivo experiments, BCA was intraperitoneal injected in tumor-implanted Fisher rats. Tumor size and edema were measured and quantified by magnetic resonance imaging (MRI) scans. In vascular organotypic glioma brain slice cultures (VOGIM) we found that BCA operates antiangiogenic and neuroprotective. In vivo MRI scans demonstrated that administered BCA as a monotherapy was effective in reducing significantly tumor-induced brain edema and showed a trend for prolonged survival. Our results revealed that dietary isoflavonoids, in particular BCA, execute toxicity toward glioma cells, antiangiogenic, and coevally neuroprotective properties, and therefore augment the range of state-of-the-art multimodal treatment approach.

Introduction
Malignant gliomas (WHO grade III and IV formerly named glioblastoma multiforme) are one of the most common primary brain tumor entities with an annual incidence rate of 5.8 in the United States and in Europe [1, 2]. The prognosis remains poor despite recent advances in multimodal treatment strategies including antiangiogenic drugs [1, 3, 4]. Severe complications associated with malignant gliomas include vasogenic and cytotoxic brain edema as well as neurodegeneration and necrosis [5–8]. A major cause of mortality in more than 60% of patients suffering from glioblastoma is due to cerebral herniation as a consequence of massive increase...
in intracranial pressure caused by uncontrolled brain edema [9, 10]. Furthermore, cerebral edema leads to neurological deterioration and hence significant reduction in quality of life. Inhibition of brain edema therefore plays a vital role in the management of malignant gliomas. So far, edema treatment in tumor patients is most commonly treated with dexamethasone [11], a synthetic glucocorticoid with potent anti-inflammatory activity. Most patients undergoing radiochemotherapy receive dexamethasone as a supportive treatment. The significant decrease in deaths related to this treatment scheme indicates the general importance of adjuvant therapeutic approaches and its impact on the course of disease [12].

Despite this, only few attempts have been made in search for nonsteroid-based alternatives in the management of cerebral edema. One proposal would be caloric restriction in influencing tumor metabolism, edema formation, and angiogenesis [13–16]. This is often carried out by increasing the dietary component of isoflavonoids, which constitute an integral part of the human diet [17–19]. Moreover, isoflavonoids such as biochanin A (BCA) and genistein (GST) have been found to exert positive influence on the inhibition of cancer induction and progression in vitro and in vivo [20–22].

Thus, the contribution of caloric restriction and dietary isoflavonoids is not well discriminated in those settings. Isoflavonoids are a large group of polyphenolic compounds occurring in plants [23]. These compounds are enriched in vegetables, fruits, and in red clover [24] and their beneficial effects are high in various chronic diseases as well as association with reduction in the general risk of developing cancer is well documented [25, 26].

The molecular mechanism of action of isoflavonoids is based on compound-specific inhibitory effects on protein tyrosine kinases, poly(ADP-ribose) polymerase cleavage, and caspase-3 activation in the case of GST [27, 28], and inhibition of glioma-derived matrix metalloproteinases and phosphorylation of Akt and eIF4E in the case of BCA [29, 30].

Here, we examined the effect of the isoflavonoid biochanin A (BCA) from the red clover (trifolium pratense), GST, and the flaxseed component secoisolariciresinol diglycoside (SDG) on nontransformed, that is, physiologic astrocytes and glioma cells. We identified BCA to be highly effective on human and rodent glioma cells while exhibiting a low-toxic profile on healthy tissue. Biochanin A can be regarded as safe with respect to adverse reaction as it does not induce cell death in healthy brain tissue. Hence, BCA prevents spontaneous neuronal damage and exerts antiangiogenic and brain swelling preventive effects in vivo. These results indicate that isoflavonoids exert a variable toxic profile and show beneficial effects in addition to established chemotherapeutics.

Material and Methods

Cell culture

Rodent glioma cell line F98, the human glioma cell line U87, and the murine glioma cell line GL261 were obtained from ATCC/LGC (Wesel, Germany). The human glioma cell line U251 was provided by Yvonne Ruebner and Rainer Fietkau (Department of Radiation Therapy, Erlangen University Hospital). Primary rat astrocytes were prepared from up to 1-month-old Wistar rats. All cells were cultured under standard humidification conditions (37°C, 5% CO₂) with Dulbecco’s modified Eagle’s medium (DMEM; Biochrom, Berlin, Germany) supplemented by 10% fetal bovine serum (Biochrom), 1% penicillin/streptomycin (Biochrom), and 1% glutamax (Gibco/Invitrogen, Darmstadt, Germany). Cells were passaged at ~80% confluence. Cells were scrapped of or trypsinized after the phosphate buffered saline (PBS) wash step. Cells were plated out in a culture flask after centrifugation (900 rpm for 5 min).

Primary astrocytes culture

Primary astrocytes were isolated from rat brains postnatal day 4 to 6 excluding the cerebellum (Charles River Laboratories, Wilmington, MA). Brains freed of meninges were placed in ice-cold Hank’s Balanced Salt Solution (HBSS) buffer without serum. Brains were further gently triturated with fire-polished Pasteur pipettes of diminishing tip diameter until tissue was uniformly homogenized. Minced brain tissue was trypsinized with 0.25% trypsin for 10 min. After resuspending and centrifugation, astrocytes were cultured in full DMEM medium (Biochrom) supplemented with 10% fetal calf serum and penicillin/streptomycin (Biochrom). From the following day on astrocyte culture flasks were agitated to separate detaching microglia.

Chemicals

BCA was purchased from Selleckchem (Absource Diagnostics, München, Germany). For in vitro and ex vivo assays, BCA was dissolved under sterile conditions in dimethylsulfoxide (DMSO) to a concentration of 50 mmol/L; for the in vivo use the concentration was 50 mg/mL. Genistein and SDG from Linum usitatissimum (flaxseed) were purchased from Sigma-Aldrich (Taufkirchen, Germany). Genistein was dissolved in pure DMSO under sterile conditions to a concentration of 100 mmol/L. Secoisolariciresinol diglucoside was prepared in DMSO in 30% DMSO/water under sterile conditions to a concentration of 10 mmol/L.
Cell viability analysis and toxicity assays

Cell viability was determined using a 3(4,5-dimethylthiazol)-2,5-diphenyltetrazolium (MTT) assay as previously described [31]. Cells were plated at an appropriate density depending on the growth rate (1000–3500 cells/well) in 96-well plates 5 h prior to the drug treatment. On the fourth day, cells were incubated with MTT solution (Roth, Karlsruhe, Germany) (5 mg/mL) for 4 h at 37°C, 5% CO₂. Cells were then lysed with 100 µL isopropanol + 0.1 N HCl. The optical density of each well was determined using the microplate reader Tecan SLT spectra (Crailsheim, Germany) set to 550 nm (wavelength correction set to 690 nm) using Tecan X Fluor4 software. Plates were normally read within 1 h of adding the isopropanol. The cells without drugs were used as control. The viability of the cells was expressed as the percentage of control. Assays were performed on at least three independent experiments.

Cell death assay and apoptosis analysis

Cell death assay was performed with propidium iodide (PI) staining purchased from Molecular Probes (Invitrogen, Darmstadt, Germany). Cells were stained for 20 min (1 µg/mL) and pictures then taken with an Olympus x71 (Tokyo, Japan). Apoptosis assays were performed with modifications as described previously [32]. Thus, cells plated at 12,000 cells/well in a 12-well plate and incubated for 4 days. Samples were washed with PBS (saved) and trypsinized. The pooled samples were fixed with 4% paraformaldehyde (PFA) on ice for 10 min, and then spun down at 1500 rpm for 5 min. Cells were stained with HOECHST 33258 (Invitrogen) (1 µg/mL) for 10 min in darkness. The suspension was added to an objective glass and mounted on cover slips. Pictures were taken with an Olympus x71 and images with cell-F software (Olympus). Cells containing fragmented nuclei were classified as apoptotic.

Vascular organotypic brain slice cultures

Brain slice cultures of 5-day-old Wistar rats (Charles River, Boston, MA) were prepared and maintained as previously described [33]. Animals were sacrificed and the brains were removed and kept under ice-cold conditions. Frontal lobes and cerebellum were dissected of the hemispheres. The remaining brain was cut into 350 μm thick horizontal slices using a vibratome (Leica VT 1000S, Bensheim, Germany). The brain slices were transferred onto ThinCert™ cell culture inserts (GreinerBioOne, Frickenhausen, Germany; pore size 0.4 µm) and subsequently transferred into six-well culture dishes (GreinerBioOne) containing 1.2 mL culture medium (MEM-HBSS, 2:1, 25% horse serum, 2% L-glutamine, 2.64 mg/mL glucose, 100 U/mL penicillin, 0.1 mg/mL streptomycin, 10 µg/mL insulin-transferrin-sodium selenite supplement, and 0.8 µg/mL vitamin C). The slices were cultured in humidified atmosphere (35°C, 5% CO₂). The medium was changed on the first day after preparation and from that time on every second day. The drug treatment started the day after the preparation and correlated with the medium change. Stably GFP-transfected F98 glioma cells (10,000 cells) (p-EGFP-N1 from BD Biosciences Clontech, Heidelberg, Germany) were implanted within a total volume of 0.1 µL medium into the entorhinal cortex (layer II and III) 1 day after slice preparation. One day after implantation and then every second day, glioma growth and cell death were evaluated using the microscope Olympus ix71. Slice cultures were incubated with 1 µg/mL PI for 20 min followed by complete medium exchange in order to visualize irreversibly damaged cells and apoptosis. Slices for pharmacology were fixed after 5 days. Slices with tumor implanted GFP-expressing F98 glioma cells were fixed after 10 days.

Angiogenesis monitoring and vessel quantification

At the indicated culture time, slices were fixed with ImmunoFixative (PBS, 4% PFA, 1.2% picric acid, pH = 7.2–7.4 with NaOH) and immunostained with rabbit anti-Laminin 1:200 (Sigma-Aldrich) for vessel analysis. Vessel density quantification was performed by the overlay grid method as described [31]. In brief, we designed 80 × 80 µm grids over layering each image and calculated the number of vessels crossing the grids.

In vivo study

Animal experiments were performed after the Franconian State approval and in congruence with the European Union guidelines governing the use of laboratory animals (no. 5425310806). All efforts were made to reduce animal numbers and pain suffering. Male Fisher rats weighing 190–210 g (Charles River) were deeply anesthetized by intraperitoneal injection of ketamine (Pfizer, Germany)/xylazine (Bayer Healthcare, Germany) (2:1) before fixing them in a stereotactic frame (David Kopf Instruments, Bilaney Consultants). Stably GFP-transfected F98 rat glioma cells were stereotactically implanted in a volume of 4 µL (100,000 cells) with a Hamilton syringe (VWR, USA) into the right frontal lobe of the animals (2-mm lateral to bregma, 4-mm depth from dura). Drug treatment started the second day after implantation, thereafter every second day. BCA dissolved in sterile DMSO (used as
vehicle) was administered through intraperitoneal injection (200 µL each time) at 50 mg/kg. Tumor implant was monitored 10 days after implantation using a clinical 3 Tesla magnetic resonance imaging (MRI) scanner (Siemens Healthcare, Siemens AG, Erlangen, Germany). A modified neurological deficit assessment was documented according to four clinical scales [6]. In brief, rats were clinically checked every day and evaluated according to neurological status (grade 0: normal; grade 1: tail weakness or tail paralysis; grade 2: hind leg paraparesis or hemiparesis; grade 3: hind leg paralysis or hemiparesis; grade 4: complete paralysis (tetraplegia), moribund stage, or death). Rats were sacrificed at grade 4. Grade 1 was defined to be the onset of neurological deficit.

**MRI determination of brain edema determination**

MRI was performed on a clinical 3 Tesla MR scanner (Magnetom Tim Trio Human MRI system, Siemens Healthcare, Siemens AG) with a 40-mm diameter, small field-of-view orbita surface coil as a receiver. Scout images and a 3DCISS sequence (repetition time = 9 msec, echo time = 5 msec, reconstructions with a slice thickness of 2 mm) were obtained in coronal, axial, and transverse planes to position the slices accurately. Ten coronal T1- and T2-weighted slices, each with 2-mm thickness and 0.2-mm separation (interslice gap) were then positioned on the transverse scout images to cover the tumor. T1-weighted images were acquired with a 384 × 307 matrix, field-of-view = 70 × 70 mm, repetition time = 507 msec, echo time = 17 msec, and a total scan time of 3 min 42 sec. For contrast-enhanced images, each animal received 0.1 mL per kg body weight of contrast agent (Gadovist 1.0; Bayer Pharma, Leverkusen, Germany) i.p. 10 min prior to the acquisition of T1-weighted sequences. The T2-weighted images were acquired with a 320 × 256 matrix, field-of-view = 91 × 91 mm, repetition time = 4500 msec, echo time = 158 msec, and a total scan time of 6 min 12 sec. Imaging analysis was performed for each rat using Osirix (GNU General Public License built-in image processing software) to outline tumor volume on the T1-weighted contrast-enhanced images. Total tumor volume was calculated as the summed area on all slices, multiplied by the slice separation, and compared to histology-derived tumor volume. Additionally, edema volume was measured by subtracting the tumor volumes as derived from T1 and T2 tumor volumes derived from the, respectively, weighted images.

**Immunofluorescence**

The rat brains of the in vivo study were fixed in 4% PFA and thereafter incubated in 20% sucrose for 3 days. The brains were frozen in liquid nitrogen and embedded in Tissue Tek. Cryosections (10 µm) were stained with rat anti-RECA-1 at 1:500 (Abd Serotec, Puchheim, Germany). Detection of bounded primary antibodies was accomplished with Alexa Fluor 568 goat anti-rabbit IgG secondary antibody and Alexa Fluor 568 goat anti-rat IgG secondary antibody (Molecular Probes, Life Technologies, Darmstadt, Germany), respectively, both at 1:1000. The cryosections were counterstained with HOECHST 33258 (Invitrogen, Life Technologies) at a concentration of 1 µg/mL.

**Statistical analysis**

Analysis was performed using unpaired two-sided Student’s t-test (MS Excel). Data from cell viability analysis and toxicity assays were obtained from at least four independent experiments. The level of significance was set at *P < 0.05. Error bars represent ±SD. For survival analysis of the in vivo study we used the GraphPad Prism software (GraphPad Software, Inc., La Jolla). Cell death intensity was quantified by Mac Biophotonics-Image J and vessel density through the overlay grid method [34] by Adobe Photoshop (Adobe Photoshop Inc., San Jose, CA).

**Results**

**Various isoflavonoids with different toxicity profiles on glioma cell growth**

In order to investigate whether isoflavonoids are generally toxic to normal differentiated brain cells, we first established the toxicity profile of various isoflavonoids on rat primary astrocytes (Fig. 1A). BCA showed no toxicity toward primary astrocytes within a wide concentration range. At maximum concentrations, BCA reduced growth of primary astrocytes to about 5% compared to control conditions (Fig. 1A, left). Both isoflavonoids GST and SDG tested within the same concentration assays showed a significant reduction in cell viability already at 10 µmol/L. The decrease in cell viability was pronounced in the case of GST, with over 60% of cells dying at 10 µmol/L GST. At 100 µmol/L GST reduced cell survival to below 5% (Fig. 1A, middle). SDG appeared less toxic, with significant decrease in cell survival to 80–85% at 50 µmol/L and 100 µmol/L, respectively (Fig. 1A, right).

We next tested the effect of these isoflavonoids on established glioma cells, first on F98 rat glioma cells (Fig. 1B). GST was more potent here in inducing cell death than BCA, especially at 50 µmol/L (Fig. 1B, left, middle). SDG appeared to be less effective in comparison to BCA and GST (Fig. 1B, right). In human glioma cells U87 (Fig. 1C) and U251 (Fig. 1D), the isoflavonoid BCA...
Figure 1. Isoflavonoids impede astrocytes and malignant glioma cell growth with differential efficiency. (A) Primary rodent astrocytes (AS) were treated with various concentrations of biochanin A (BCA), genistein (GST), and secoisolariciresinol diglucoside (SDG) and cell survival was monitored. BCA is nontoxic for primary astrocytes even at high concentrations. GST induces astrocyte cell death at low concentration. SDG is toxic to astrocytes from 50 \( \mu \text{mol/L} \) onward. (B) Rodent malignant gliomas (F98) were treated with various concentrations of BCA, GST, and SDG and glioma cell survival was monitored. All three isoflavonoids are toxic already at low concentrations. (C, D) Human malignant gliomas (C, U87; D, U251) were treated with various concentrations of BCA, GST, and SDG and glioma cell survival was monitored. Note that SDG does not affect human glioma growth. BCA and GST causes cell death. (E) Murine malignant gliomas (GL261) were treated with various concentrations of BCA, GST, and SDG and glioma cell viability was measured. Differences were considered statistically significant with values mean \( \pm \) SD (n \( \geq \) 3 per group; unpaired two-sided \( t \)-test, \( P < 0.05 \)).
showed significant reduction in cell growth of down to 10% in comparison to the controls (Fig. 1C and D, middle). It was interesting to note that SDG did not affect cell proliferation of human U87 and U251 glioma cells, which grew equally well in comparison to untreated controls (Fig. 1C and D, right). We also tested these isoflavonoids on the established murine GL261 glioma cells (Fig. 1E). Although BCA (Fig. 1E, left) and SDG (Fig. 1E, right) were both effective in reducing GL261 cell growth from 50 μmol/L onward, BCA showed a broader efficacy in all other tested glioma cell lines. GST reduced the cell viability of GL261 40–80% (Fig. 1E, middle) and had the highest potency of the tested isoflavonoids. The growth inhibitory effect was observed on all cells independently of their malignant status already at the lowest concentration (10 μmol/L) (Fig. 1A–E, middle). Since BCA is solved in DMSO, we further tested the effects of DMSO on astrocytes and glioma cell proliferation (Fig. 2). DMSO appeared to reduce cell viability at high concentrations in astrocytes, F98 and U87 glioma cells (Fig. 2A). Next, we compared the cell viability of BCA treatment with the respective DMSO-matched controls. These results confirmed our initial findings that BCA is gliomatoxic and has no damaging effects on primary astrocytes (Fig. 2B).

**Biochanin A induces apoptotic cell death in human glioma cells**

The results of the BCA treatment could be further confirmed by monitoring cell death with PI staining in human U251 glioma cells (Fig. 3A). With increasing concentrations, BCA-treated gliomas exhibited higher numbers of dead cells. The apoptosis assay on BCA-treated glioma cells also supported the cell viability results. The extent of apoptosis was evaluated by morphological analysis of the nuclei. Fragmented nuclei were found in U251-treated cells stained for nuclei with Hoechst 33342, which were assessed as an indicator for apoptosis (Fig. 3B). The dose–response analysis of BCA on glioma cells could be confirmed by investigating apoptotic cell death (Fig. 3B).

**Biochanin A operates neuroprotective in an organotypic brain environment**

We next tested whether BCA affects neuronal survival and integrity. For this native, rat brain slices were treated with the concentration of BCA already tested in the cell viability assays (Fig. 4). Advantage of this ex vivo model is that it enables pharmacological testing in real-time mode [33]. Brain sections were cut and slices were cultured on permeable PET membranes bathed in culture medium. Treatment was performed by adding BCA into the medium and cell death was assessed with PI after 5 days in culture. Quantitative results showed a significant cell death decrease by 30% at 50 μmol/L BCA (Fig. 4A). The slices were then fixed and stained for laminin and subsequently vessel density was determined by the overlay grid method [34]. We found that the vascular density decreased by 15% in 100 μmol/L BCA-treated brain slices compared to non-treated brain tissues (Fig. 4B). We conclude that BCA acts neuroprotective and also vasculoprotective within an organotypic brain environment.

**Biochanin A reduces glioma tumor growth and exhibits antiangiogenic properties**

We next implanted glioma cells into normal brain tissue and monitored tumor growth and brain tissue integrity. Glioma tumors showed invasive cell growth and destructive effects on its host environment (Fig. 5). After 8 days in culture, cell death was measured with PI in both the normal brain tissue in the control group and the BCA-treated group. There was no visible difference (Fig. 5A, left). In analyzing the effects of BCA on treatment with 50 μmol/L revealed enhanced tumor cell death. In this context, BCA acted as a glioma-toxic agent (Fig. 5A, middle). Subsequent investigations of tumor growth over time confirmed the initial findings in single-cell cultures that BCA is glioma toxic in a concentration-dependent manner. Concentrations of 50 μmol/L BCA reduced tumor growth up to 25%, which could not be increased by higher concentrations of BCA (Fig. 5A, right). After 10 days in culture, tumor-implanted brain slices were fixed and stained for laminin. Noteworthy, vessel density in peritumoral areas was visibly reduced following BCA treatment. Quantitative results verified these findings, showing a decrease by 30–40% compared to controls (Fig. 5B).

**Biochanin A reduces tumor-related cerebral edema and alleviates clinical deterioration in vivo**

Since BCA appeared to be effective as an antitumor angiogenic and neuroprotective agent, we investigated this isoflavonoid in vivo. For this, we stereotactically implanted glioma cells into rat brains and monitored tumor growth by MRI scans (Fig. 6). Nine days after implantation, in vivo tumor monitoring by T1-weighted MRI scans revealed that BCA-treated gliomas tended to be smaller than the control tumor group (Fig. 6A). Three Tesla contrast agent-enhanced T1-weighted MRI scans further demonstrated reduced perifocal cerebral edema in
animals treated with intraperitoneal BCA (Fig. 6A). In the assessment of onset of clinical signs after tumor implantation, BCA-treated animals developed neurological deficits later than control-treated animals (Fig. 6B). Monitoring the clinical progression of neurological deficits in animals with BCA treatment showed that they exhibited fewer
**Figure 3.** Biochanin A induces apoptosis in human glioma cells. (A) Human glioma (U251) cell death after BCA treatment was monitored in vivo by propidium iodide (PI). Dead cells take up the PI dye and appear as white-stained nuclei. Scale bar represents 100 µm. (B) Apoptosis of human gliomas (U251) monitored by HOECHST dye. Fragmented nuclei are accumulating after BCA treatment (arrow heads). Scale bar represents 50 µm.

**Figure 4.** Biochanin A is neuro- and vasculoprotective in organotypic brain environment. (A) BCA treatment showed neuronal protective effects in rat native brain slices. After 5 days culture, cell death was evaluated (propidium iodide). A quantity of 50 µmol/L BCA showed a significant decrease in cell death. Scale bar represents 1 mm. Differences were considered statistically significant with values mean ± SD (*P < 0.01, unpaired two-sided t-test, n ≥ 14 per group). (B) Vessel density was significantly reduced at 100 µmol/L BCA treatment. Scale bar represents 50 µm. Differences were considered statistically significant with values mean ± SD (*P < 0.01, unpaired two-sided t-test, n ≥ 10 per group).
neurological deficits in the first 20 days after tumor implantation (Fig. 6C). Although the difference was not statistically significant, the Kaplan–Meier survival analysis showed that BCA-treated animals tended to survive longer than controls (Fig. 6D).

We next investigated tumor angiogenesis in vivo by comparing the vasculature of BCA-treated animals with that of the control group. Staining for the vascular endothelial cell marker RECA revealed no obvious differences between these groups (Fig. 6E). Altogether, our study revealed that BCA treatment can alleviate tumor-induced brain edema in vivo.

**Discussion**

In this study, we investigated the impact of isoflavonoids on glioma morphology and function. Our results demonstrate that BCA in particular can reduce the oncogenic progression of glioma cells. Investigation of different isoflavonoids in identical conditions revealed that they exert different toxic and efficacy profiles. Our study shows that BCA significantly affects malignant gliomas while exhibiting a low toxic profile toward nonmalignant astrocytes. Having studied the effects of various isoflavonoids in the context of cancer cells, our investigations showed that the toxicity profile of BCA, GST, and SDG differ profoundly. Although GST is very effective in inducing glioma cell death, it is highly toxic for primary astrocytes. Prior reports showed on the contrary that GST slightly reduces human astrocyte viability within 24 h and led to increased reactive oxygen species formation [21]. Our study, however, included analysis over an extended time period of 4 days within this timeframe GST and SDG exhibited toxicity toward primary astrocytes. In the identical setting, however, cell growth and viability of primary astrocytes were not affected toward BCA treatment. Since BCA and
BCA Operates Antiangiogenic and Neuroprotective

(A) Control vs BCA

T1+CM

T2

(B) Onset of neurological deficits (days)

Control vs BCA

(C) Clinical score (grade 1-4)

(D) Survival [%]

Control vs BCA

(E) RECA, GFP, DAPI, MERGE

Control vs BCA
Our ex vivo and in vivo investigations revealed that BCA exhibits antiedematous and antiangiogenic properties. BCA decreased tumor-associated edema and delayed the onset of clinical deterioration. These results indicate that BCA exhibits various toxicity profiles and can be beneficial as a potential substitute to established chemotherapeutic agents. Caloric restriction is often performed by dietary components such as isoflavonoids constituting an integral part of the diet [17, 19]. Whether the reported beneficial effects of caloric restriction can be traced back to the effects of BCA remains to be shown [13–16]. Since the development of tumor-induced edema has two pathogenic components, that is, a cytotoxic and vasogenic, it remains a matter of speculation as to which mechanism primarily contributes to the BCA-associated effects like normalization of tumor vessels and reduction in tumor-induced cell death. Nevertheless, the management of cerebral edema [42], currently comprising primarily of treatment with dexamethasone [11], represents a major component of the battle against brain-tumor associated comorbidities. Thus, BCA may provide a dietary therapeutic approach with beneficial and supportive effects for the management of tumor-induced brain edema.

**Conclusion**

In summary, our results show that dietary isoflavonoids differ in their impact on glioma cells. BCA in particular is vasculo- and neuroprotective, and can alleviate tumor-induced brain edema. These data further indicate that BCA can synergistically support multimodal therapies with a low toxic profile. However, BCA alone as a monotherapy does not seem to be effective, at least in case of intraperitoneal administration.

**Acknowledgments**

We thank Irene Emmann, Stefan Hock and Gökçe Hatipoğlu for continuous laboratory support and critical...
discussions. We are grateful for the valuable help of Birgitte Hoefler, Silke Speck, and Petra Kelly in lending continuous administrative support. We thank Yvonne Ruebner and Rainer Fietkau (Department of Radiotherapy, Erlangen University Hospital) for providing human glioma cells U251.

**Conflict of Interest**

None declared.

**References**

1. Dolecek, T. A., J. M. Propp, N. E. Stroup, and C. Kruchko. 2012. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 14(Suppl. 5): v1–v49.
2. Kohler, B. A., E. Ward, B. J. McCarthy, M. J. Schymura, L. A. Ries, and C. Ehemann, et al. 2011. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J. Natl. Cancer Inst. 103:714–736.
3. Siegel, R., D. Naishadham, and A. Jemal. 2012. Cancer statistics, 2012. CA Cancer J. Clin. 62:10–29.
4. Dunn, G. P., M. L. Rinne, J. Wykosky, G. Genovese, S. N. Quayle, I. F. Dunn, et al. 2012. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 26:756–784.
5. Shah, U., and T. Morrison. 2013. A review of the symptomatic management of malignant gliomas in adults. J. Natl. Compr. Canc. Netw. 11:424–429.
6. Sacaskan, N. E., A. Heckel, E. Hahnen, T. Engelhorn, A. Doerfler, O. Ganslandt, et al. 2008. Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat. Med. 14:629–632.
7. Savaskan, N. E., and I. Y. Eyupoglu. 2010. xCT modulation in gliomas: relevance to energy metabolism and tumor microenvironment normalization. Ann. Anat. 192:309–313.
8. Watkins, S., and H. Sontheimer. 2012. Unique biology of gliomas: challenges and opportunities. Trends Neurosci. 35:546–556.
9. Batchelor, T. T., A. G. Sorensen, E. di Tomaso, W. T. Zhang, D. G. Duda, K. S. Cohen, et al. 2007. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95.
10. Silbergeld, D. L., R. C. Rostomily, and E. C. Jr Alvord. 1991. The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults. J. Neurooncol. 10:179–185.
11. Kaal, E. C., and C. J. Vecht. 2004. The management of brain edema in brain tumors. Curr. Opin. Oncol. 16:593–600.
12. Hempen, C., E. Weiss, and C. F. Hess. 2002. Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? Support Care Cancer 10:322–328.
13. Mukherjee, P., L. E. Abate, and T. N. Seyfried. 2004. Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clin. Cancer Res. 10:5622–5629.
14. Jiang, Y. S., and F. R. Wang. 2013. Caloric restriction reduces edema and prolongs survival in a mouse glioma model. J. Neurooncol. 114:25–32.
15. Marsh, J., P. Mukherjee, and T. N. Seyfried. 2008. Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma. Clin. Cancer Res. 14:7751–7762.
16. Mulrooney, T. J., J. Marsh, I. Urits, T. N. Seyfried, and P. Mukherjee. 2011. Influence of caloric restriction on constitutive expression of NF-kappaB in an experimental mouse astrocytoma. PLoS ONE 6:e18085.
17. Pallauf, K., and G. Rimbach. 2013. Autophagy, polyphenols and healthy ageing. Ageing Res. Rev. 12:237–252.
18. Willcox, D. C., B. J. Willcox, H. Todoriki, and M. Suzuki. 2009. The Okinawan diet: health implications of a low-calorie, nutrient-dense, antioxidant-rich dietary pattern low in glycemic load. J. Am. Coll. Nutr. 28(Suppl.):S05–S16.
19. Chung, S., H. Yao, S. Caito, J. W. Hwang, G. Arunachalam, and I. Rahman. 2010. Regulation of SIRT1 in cellular functions: role of polyphenols. Arch. Biochem. Biophys. 501:79–90.
20. Lee, Y. S., T. H. Kim, K. J. Cho, and J. J. Jang. 1992. Inhibitory effects of biochanin A on benzo(a)pyrene induced carcinogenesis in mice. In Vivo 6:283–286.
21. Das, A., N. L. Banik, and S. K. Ray. 2010. Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes. Cancer 116:164–176.
22. Brown, A., P. Jolly, and H. Wei. 1998. Genistein modulates neuroblastoma cell proliferation and differentiation through induction of apoptosis and regulation of tyrosine kinase activity and N-myc expression. Carcinogenesis 19:991–997.
23. Wang, X. 2011. Structure, function, and engineering of enzymes in isoflavonoid biosynthesis. Funct. Integr. Genomics 11:13–22.
24. Kirkman, L. M., J. W. Lampe, D. R. Campbell, M. C. Martini, and J. L. Slavin. 1995. Urinary lignan and isoflavonoid excretion in men and women consuming vegetable and soy diets. Nutr. Cancer 24:1–12.
25. Hlebowicz, J., I. Drake, B. Gullberg, E. Sonestedt, P. Wallström, M. Persson et al. 2013. A high diet quality is associated with lower incidence of cardiovascular events in the Malmo diet and cancer cohort. PLoS ONE 8:e71095.
26. Sharma, S., S. Vik, M. Pakseresht, L. Shen, and L. N. Kolonel. 2013. Diet impacts mortality from cancer: results from the multiethnic cohort study. Cancer Causes Control 24:685–693.
27. Paillart, C., E. Carlier, D. Guedin, B. Dargent, and F. Couraud. 1997. Direct block of voltage-sensitive sodium channels by genistein, a tyrosine kinase inhibitor. J. Pharmacol. Exp. Ther. 280:521–526.
28. Li, Y., and F. H. Sarkar. 2002. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin. Cancer Res. 8:2369–2377.
29. Puli, S., J. C. Lai, and A. Bhushan. 2006. Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) cells by isoflavones. J. Neurooncol. 79:135–142.
30. Puli, S., A. Jain, J. C. Lai, and A. Bhushan. 2010. Effect of combination treatment of rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells. Neurochem. Res. 35:986–993.
31. Fan, Z., T. Sehm, M. Rauh, M. Buchfelder, I. Y. Eyupoglu, and N. E. Savaskan. 2014. Dexamethasone alleviates tumor-associated brain damage and angiogenesis. PLoS One. 9:e93264.
32. Savaskan, N. E., A. Borchert, A. U. Brauer, and H. Kuhn. 2007. Role for glutathione peroxidase-4 in brain development and neuronal apoptosis: specific induction of enzyme expression in reactive astrocytes following brain injury. Free Radic. Biol. Med. 43:191–201.
33. Eyupoglu, I. Y., E. Hahnen, A. Heckel, F. A. Siebzehnrübl, R. Buslei, R. Fahlbusch, et al. 2005. Malignant glioma-induced neuronal cell death in an organotypic glioma invasion model. Technical note. J. Neurosurg. 102:738–744.
34. Hock, S. W., Z. Fan, M. Buchfelder, I. Y. Eyupoglu, and N. E. Savaskan. 2013. Brain tumor-induced angiogenesis: approaches and bioassays. P. 20 in T. Lichtor, ed. Evolution of the molecular biology of brain tumors and the therapeutic implications. vol. 1. ISBN 978-953-51-0989-1.
35. Medjakovic, S., and A. Jungbauer. 2008. Red clover isoflavones biochanin A and formononetin are potent ligands of the human aryl hydrocarbon receptor. J. Steroid Biochem. Mol. Biol. 108:171–177.
36. Platten, M., C. Opitz, and W. Wick. 2012. The aryl hydrocarbon receptor as a promoter of malignant glioma. Cell Cycle 11:643–644.
37. Moon, Y. J., D. A. Brazeau, and M. E. Morris. 2007. Effects of flavonoids genistein and biochanin A on gene expression and their metabolism in human mammary cells. Nutr. Cancer 57:48–58.
38. Tang, L., R. Singh, Z. Liu, and M. Hu. 2009. Structure and concentration changes affect characterization of UGT isoflavone-specific metabolism of isoflavones. Mol. Pharm. 6:1466–1482.
39. Buckingham, S. C., S. L. Campbell, B. R. Haas, V. Montana, S. Robel, T. Ogunrinu, et al. 2011. Glutamate release by primary brain tumors induces epileptic activity. Nat. Med. 17:1269–1274.
40. Eyupoglu, I. Y., M. Buchfelder, and N. E. Savaskan. 2013. Surgical resection of malignant gliomas-role in optimizing patient outcome. Nat. Rev. Neurol. 9:141–151.
41. Preusser, M., S. de Ribaupierre, A. Wohrer, S. C. Erridge, M. Hegen, M. Weller, et al. 2011. Current concepts and management of glioblastoma. Ann. Neurol. 70:9–21.
42. Jelsma, R., and P. C. Bucy. 1967. The treatment of glioblastoma multiforme of the brain. J. Neurosurg. 27:388–400.